Verition Fund Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,439
| Closed | -$212K | – | 2809 |
|
|
2023
Q3 | $212K | Sell |
11,439
-37,038
| -76% | -$419K | ﹤0.01% | 1945 |
|
|
2023
Q2 | $536K | Buy |
48,477
+36,189
| +295% | +$504K | 0.01% | 1203 |
|
|
2023
Q1 | $165K | Buy |
12,288
+935
| +8% | +$16.2K | ﹤0.01% | 1815 |
|
|
2022
Q4 | $140K | Sell |
11,353
-17,067
| -60% | -$242K | ﹤0.01% | 1813 |
|
|
2022
Q3 | $396K | Buy |
28,420
+13,576
| +91% | +$219K | ﹤0.01% | 2048 |
|
|
2022
Q2 | $205K | Buy |
+14,844
| New | +$238K | ﹤0.01% | 1930 |
|
|
2021
Q2 | – | Sell |
-12,432
| Closed | -$287K | – | 2223 |
|
|
2021
Q1 | $287K | Buy |
+12,432
| New | +$347K | ﹤0.01% | 1150 |
|
|
2019
Q3 | – | Sell |
-2,588
| Closed | -$206K | – | 1398 |
|
|
2019
Q2 | $206K | Buy |
+2,588
| New | +$232K | 0.01% | 973 |
|
|
2016
Q4 | – | Sell |
-2,378
| Closed | -$391K | – | 1470 |
|
|
2016
Q3 | $391K | Buy |
+2,378
| New | +$375K | 0.04% | 624 |
|
|
2015
Q2 | – | Sell |
-1,442
| Closed | -$407K | – | 737 |
|
|
2015
Q1 | $407K | Buy |
+1,442
| New | +$312K | 0.05% | 136 |
|
|
2014
Q4 | – | Sell |
-2,529
| Closed | -$599K | – | 711 |
|
|
2014
Q3 | $599K | Buy |
+2,529
| New | +$645K | 0.08% | 198 |
|
Verition Fund Management's ICPT Position: Q4 2023 in Review
Verition Fund Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 11,439 shares — an estimated $212K sold.
Verition Fund Management first reported a position in ICPT in Q3 2014 and held it in 11 quarters. The position peaked at $599K in Q3 2014. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Verition Fund Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Verition Fund Management sold 11,439 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $212K.
- Verition Fund Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 11 quarters.
- Verition Fund Management's Intercept Pharmaceuticals, Inc. position peaked at $599K in Q3 2014.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.